Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
A phase I/II study of golidocitinib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T-cell lymphoma.
- Authors
- Kim, WS[Kim, Won Seog]; Yoon, DH[Yoon, Dok Hyun]; Song, YQ[Song, Yuqin]; Yang, HY[Yang, Haiyan]; Cao, JN[Cao, Junning]; Ji, DM[Ji, Dongmei]; Koh, Y[Koh, Youngil]; Jing, HM[Jing, Hongmei]; Eom, HS[Eom, Hyeon Seok]; Kwak, JY[Kwak, Jae-Yong]; Lee, WS[Lee, Won-Sik]; Lee, JS[Lee, Jong Seok]; Shin, HJ[Shin, Ho-Jin]; Jin, J[Jin, Jie]; Wang, M[Wang, Mei]; Li, JR[Li, Jingrun]; Huang, XB[Huang, Xubin]; Deng, XY[Deng, Xueyuan]; Yang, ZF[Yang, Zhenfan]; Zhu, J[Zhu, Jun]
- Issue Date
- 1-Jun-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.16
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 16
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.